• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $CRVS

    Corvus Pharmaceuticals Inc.

    Subscribe to $CRVS
    $CRVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is CPI-006, an anti-CD73 monoclonal antibody, which is in Phase I/Ib clinical trial that inhibits the production of adenosine and activate various immune cells, as Phase III clinical trial of CPI-006 for COVID-19. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase Ib/II clinical trial for adenosine, an immune checkpoint. Its preclinical stage products include CPI-182, an antibody to block neutrophil function and migration, and myeloid derived suppressor cells; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals for the development its pipeline of targeted investigational medicines. The company was incorporated in 2014 and is based in Burlingame, California.

    IPO Year: 2016

    Exchange: NASDAQ

    Website: corvuspharma.com

    Peers

    $ITOS
    $RCUS
    $CANF

    Recent Analyst Ratings for Corvus Pharmaceuticals Inc.

    DatePrice TargetRatingAnalyst
    1/2/2025$11.00Buy
    H.C. Wainwright
    8/18/2023$7.00Outperform
    Oppenheimer
    12/3/2021$5.00 → $8.00Overweight
    Cantor Fitzgerald
    12/1/2021$8.00Buy
    Jefferies
    8/3/2021$4.00 → $3.50Neutral
    Mizuho
    7/16/2021$9.50 → $6.00Buy
    HC Wainwright & Co.
    See more ratings

    Corvus Pharmaceuticals Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Grais Linda

      4 - Corvus Pharmaceuticals, Inc. (0001626971) (Issuer)

      6/16/25 4:28:00 PM ET
      $CRVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Clark Ian T

      4 - Corvus Pharmaceuticals, Inc. (0001626971) (Issuer)

      6/16/25 4:27:33 PM ET
      $CRVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Morrison Scott W

      4 - Corvus Pharmaceuticals, Inc. (0001626971) (Issuer)

      6/16/25 4:27:07 PM ET
      $CRVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Thompson Peter A.

      4 - Corvus Pharmaceuticals, Inc. (0001626971) (Issuer)

      6/16/25 4:26:41 PM ET
      $CRVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Officer Jones William Benton exercised 19,357 shares at a strike of $3.50, increasing direct ownership by 13% to 173,130 units (SEC Form 4)

      4 - Corvus Pharmaceuticals, Inc. (0001626971) (Issuer)

      6/6/25 4:26:07 PM ET
      $CRVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President and CEO Miller Richard A Md exercised 559,073 shares at a strike of $3.50, increasing direct ownership by 97% to 1,136,707 units (SEC Form 4)

      4 - Corvus Pharmaceuticals, Inc. (0001626971) (Issuer)

      5/9/25 4:09:21 PM ET
      $CRVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Van Den Broek Richard

      4 - Corvus Pharmaceuticals, Inc. (0001626971) (Issuer)

      4/9/25 5:26:56 PM ET
      $CRVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New insider Van Den Broek Richard claimed ownership of 160,000 shares (SEC Form 3)

      3 - Corvus Pharmaceuticals, Inc. (0001626971) (Issuer)

      4/9/25 5:26:25 PM ET
      $CRVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Business Officer Arcara Jeffrey

      4 - Corvus Pharmaceuticals, Inc. (0001626971) (Issuer)

      12/23/24 4:40:19 PM ET
      $CRVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Officer Jones William Benton

      4 - Corvus Pharmaceuticals, Inc. (0001626971) (Issuer)

      12/23/24 4:39:46 PM ET
      $CRVS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Corvus Pharmaceuticals Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright initiated coverage on Corvus Pharmaceuticals with a new price target

      H.C. Wainwright initiated coverage of Corvus Pharmaceuticals with a rating of Buy and set a new price target of $11.00

      1/2/25 7:32:41 AM ET
      $CRVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oppenheimer initiated coverage on Corvus Pharmaceuticals with a new price target

      Oppenheimer initiated coverage of Corvus Pharmaceuticals with a rating of Outperform and set a new price target of $7.00

      8/18/23 8:04:45 AM ET
      $CRVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald reiterated coverage on Corvus Pharmaceuticals with a new price target

      Cantor Fitzgerald reiterated coverage of Corvus Pharmaceuticals with a rating of Overweight and set a new price target of $8.00 from $5.00 previously

      12/3/21 9:11:26 AM ET
      $CRVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jefferies resumed coverage on Corvus Pharmaceuticals with a new price target

      Jefferies resumed coverage of Corvus Pharmaceuticals with a rating of Buy and set a new price target of $8.00

      12/1/21 7:53:33 AM ET
      $CRVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mizuho reiterated coverage on Corvus Pharmaceuticals with a new price target

      Mizuho reiterated coverage of Corvus Pharmaceuticals with a rating of Neutral and set a new price target of $3.50 from $4.00 previously

      8/3/21 7:04:32 AM ET
      $CRVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on Corvus Pharmaceuticals with a new price target

      HC Wainwright & Co. reiterated coverage of Corvus Pharmaceuticals with a rating of Buy and set a new price target of $6.00 from $9.50 previously

      7/16/21 6:08:41 AM ET
      $CRVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald initiated coverage on Corvus Pharmaceuticals with a new price target

      Cantor Fitzgerald initiated coverage of Corvus Pharmaceuticals with a rating of Overweight and set a new price target of $10.00

      5/27/21 7:27:33 AM ET
      $CRVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on Corvus Pharmaceuticals with a new price target

      HC Wainwright & Co. reiterated coverage of Corvus Pharmaceuticals with a rating of Buy and set a new price target of $9.50 from $12.00 previously

      3/26/21 6:22:50 AM ET
      $CRVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Corvus Pharmaceuticals downgraded by Mizuho with a new price target

      Mizuho downgraded Corvus Pharmaceuticals from Buy to Neutral and set a new price target of $4.00 from $7.00 previously

      2/10/21 6:21:50 AM ET
      $CRVS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Corvus Pharmaceuticals Inc. Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Jones William Benton bought $34,624 worth of shares (20,000 units at $1.73), increasing direct ownership by 15% to 153,773 units (SEC Form 4)

      4 - Corvus Pharmaceuticals, Inc. (0001626971) (Issuer)

      5/7/24 5:06:34 PM ET
      $CRVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Miller Richard A Md bought $1,000,000 worth of shares (577,634 units at $1.73) (SEC Form 4)

      4 - Corvus Pharmaceuticals, Inc. (0001626971) (Issuer)

      5/7/24 5:05:52 PM ET
      $CRVS
      Biotechnology: Pharmaceutical Preparations
      Health Care